Journal issues > Issue 1, February 2020 > Highlights in red blood cell disorders

Highlights in red blood cell disorders

Summary

In the field of red blood cell disorders, ASH 2019 mainly focused on sickle cell disease (SCD). Current disease-modifying therapeutic options for SCD consist of hydroxyurea and chronic transfusions but none of them can fully prevent complications and both have their drawbacks. A haematopoietic stem cell transplantation is the only curative option to date. Yet, frequently a compatible donor is missing. ASH 2019 featured several abstracts on optimising disease-modifying therapies as well as curative options, such as gene therapy. A selection of abstracts is discussed below.

(BELG J HEMATOL 2020;11(1):21–6)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top